CA2422059A1 - Methods and products related to low molecular weight heparin - Google Patents
Methods and products related to low molecular weight heparin Download PDFInfo
- Publication number
- CA2422059A1 CA2422059A1 CA002422059A CA2422059A CA2422059A1 CA 2422059 A1 CA2422059 A1 CA 2422059A1 CA 002422059 A CA002422059 A CA 002422059A CA 2422059 A CA2422059 A CA 2422059A CA 2422059 A1 CA2422059 A1 CA 2422059A1
- Authority
- CA
- Canada
- Prior art keywords
- sample
- polysaccharide
- delta
- composition
- lmwh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
Abstract
The invention relates to methods and products for characterizing and using polysaccharides. Low molecular weight heparin products and methods of use ar e described. Methods for characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin are also described .
Claims (101)
1. A method of analyzing a sample comprising:
(A) applying an experimental constraint to a polysaccharide in a sample, to produce a modified polysaccharide, having a signature component, (B) detecting the presence of the signature component, in the sample as an indication that the polysaccharide is present in the sample, and (C) determining the presence or absence of the signature component to analyze the sample.
(A) applying an experimental constraint to a polysaccharide in a sample, to produce a modified polysaccharide, having a signature component, (B) detecting the presence of the signature component, in the sample as an indication that the polysaccharide is present in the sample, and (C) determining the presence or absence of the signature component to analyze the sample.
2. The method of claim 1, wherein the signature component has a known biological activity.
3. The method of claim 1, wherein the signature component is biologically inactive.
4. The method of claim 1, wherein the experimental constraint applied to the sample is capillary electrophoresis.
5. The method of claim 1, wherein the experimental constraint applied to the sample is high pressure liquid chromatography.
6. The method of claim 1, wherein the experimental constraint applied to the sample is gel permeation chromatography.
7. The method of claim 1, wherein the experimental constraint applied to the sample is nuclear magnetic resonance.
8. The method of claim 1, wherein the sample is a batch of polysaccharide and the signature component is used to monitor the purity of the batch by determining the amount of signature component in the batch.
9. The method of claim 2, wherein the method of analysis is a method for monitoring the presence of active components in the sample, wherein the presence of the signature component in the sample is indicative of an active component in the sample.
10. The method of claim 3, wherein the method of analysis is a method for monitoring the presence of active components in the sample, wherein the presence of the signature component in the sample is indicative of a sample lacking a specific activity.
11. The method of claim 2, wherein the method of analysis is a method for determining the amount of active components in the sample by determining the amount of signature component in the sample.
12. The method of claim 2, wherein the method is performed on at least two samples and wherein the relative amounts of signature component in each of the at least two samples is determined, wherein the highest relative level of signature component is indicative of the most active sample.
13. The method of claim 2, further comprising the use of the signature component to identify biologically active molecules.
14. The method of claim 13, wherein the signature component is used to screen a library.
15. The method of claim 1, wherein the signature component is a biologically active portion of a polysaccharide.
16. The method of claim 15, wherein the biologically active portion of polysaccharide is a tetrasaccharide of the AT-III biding domain of heparin.
17. The method of claim 15, wherein the biologically active portion of polysaccharide is a tetrasaccharide of the FGF biding domain of heparin.
18. The method of claim 1, wherein the experimental constraint applied to the sample is digestion with an exoenzyme.
19. The method of claim 1, wherein the experimental constraint applied to the sample is digestion with an endoenzyme.
20. The method of claim 1, wherein the experimental constraint applied to the sample is chemical digestion.
21. The method of claim 1, wherein the experimental constraint applied to the sample is chemical modification.
22. The method of claim 1, wherein the experimental constraint applied to the sample is modification with an enzyme.
23. The method of claim 1, wherein the polysaccharide in the sample is compared to a reference database of polysaccharides of identical size as the polysaccharide, wherein the polysaccharides of the reference database have also been subjected to the same experimental constraints as the polysaccharide in the sample, wherein the comparison provides a compositional analysis of the sample polysaccharide.
24. The method of claim 1, wherein the polysaccharide is a glycosaminoglycan.
25. The method of claim 1, wherein the polysaccharide is low molecular weight heparin.
26. The method of claim 1, wherein the polysaccharide is heparin.
27. The method of claim 1, wherein the polysaccharide is a biotechnologically prepared heparin.
28. The method of claim 1, wherein the polysaccharide is a chemically modified heparin.
29. The method of claim 1, wherein the polysaccharide is a synthetic heparin.
30. The method of claim 1, wherein the polysaccharide is heparan sulfate.
31. The method of claim 1, wherein the sample is a pharmaceutical product.
32. The method of claim 1, wherein the sample is biological sample.
33. The method of claim 1, wherein the sample is a blood sample.
34. The method of claim 1, wherein the signature component is one of the peaks corresponding to any One Of .DELTA.UH NAC,6S GH NS,3S,6S, .DELTA.UH
NS,6SC GH NS,3S,6S;
.DELTA.UH NAC,6S GH NS,3S; or .DELTA.UH NS,6S GH NS,3S.
NS,6SC GH NS,3S,6S;
.DELTA.UH NAC,6S GH NS,3S; or .DELTA.UH NS,6S GH NS,3S.
35. A kit for analyzing a polysaccharide sample comprising:
(A) a control composition for identifying a signature component of a polysaccharide, (B) and instructions for applying an experimental constraint to a polysaccharide sample to produce a modified polysaccharide having a signature component characteristic of the polysaccharide and for comparing the modified polysaccharide to the control composition to identify the presence or absence of the signature component.
(A) a control composition for identifying a signature component of a polysaccharide, (B) and instructions for applying an experimental constraint to a polysaccharide sample to produce a modified polysaccharide having a signature component characteristic of the polysaccharide and for comparing the modified polysaccharide to the control composition to identify the presence or absence of the signature component.
36. The kit of claim 35, wherein the polysaccharide is a glycosaminoglycan.
37. The kit of claim 35, wherein the polysaccharide is low molecular weight heparin.
38. The kit of claim 35, wherein the polysaccharide is heparin.
39. The kit of claim 35, wherein the polysaccharide is heparan sulfate.
40. The kit of claim 35, wherein the polysaccharide is biotechnologically prepared heparin.
41. The kit of claim 35, wherein the polysaccharide is a chemically modified heparin.
42. The kit of claim 35, wherein the polysaccharide is a synthetic heparin.
43. The kit of claim 35 further comprising a composition for applying an experimental constraint to the polysaccharide sample.
44. The lit of claim 43, wherein the composition is an exoenzyme.
45. The kit of claim 43, wherein the composition is an endoenzyme.
46. The kit of claim 43, wherein the signature component a tetrasaccharide of the AT-III biding domain of heparin.
47. The kit of claim 43, wherein the signature component a tetrasaccharide of the FGF biding domain of heparin.
48. The kit of claim 43, wherein the signature component is one of the peaks corresponding to any one Of .DELTA.UH NAC,6S GH NS,3S,6S, .DELTA.UH NS,6S GH
NS,3S,6S;
.DELTA.UH NAC,6S GH NS,3S ; or .DELTA.UH NS,6S GH NS,3S.
NS,3S,6S;
.DELTA.UH NAC,6S GH NS,3S ; or .DELTA.UH NS,6S GH NS,3S.
49. The kit of claim 35, wherein the instructions include the steps for quantifying the signature component of the polysaccharide in the sample.
50. A method for evaluating the quality of a polysaccharide sample comprising the steps of:
identifying a component within the polysaccharide sample, determining a quantitative value of the amount of component, wherein the quantitative value of the component is indicative of the quality of the polysaccharide sample.
identifying a component within the polysaccharide sample, determining a quantitative value of the amount of component, wherein the quantitative value of the component is indicative of the quality of the polysaccharide sample.
51. The method of claim 50, wherein the method involves identifying at least two components within the polysaccharide sample and determining a quantitative value of the amount of each of the at least two components to evaluate the quality of the polysaccharide sample.
52. The method of claim 51, wherein the quantitative value is calculated as the area under the curve when the sample is processed by capillary electrophoresis.
53. The method of claim 51, wherein the quantitative value is calculated as the response factor.
54. The method of claim 51, wherein the quantitative value is calculated as the percent relative amount of each fraction present in the sample.
55. The method of claim 51, wherein the step of calculating the percent relative amount of each fraction present in the sample is determined according to the below equation:
PRA = RF x AUC%R
wherein PRA = percent relative amount of each fraction RF = response factor AUC%R = percent relative AUC [(100 x AUC C)/AUC T)]
AUC C = Area under the curve for one component AUC T = the sum of the Area under the curve for all components.
PRA = RF x AUC%R
wherein PRA = percent relative amount of each fraction RF = response factor AUC%R = percent relative AUC [(100 x AUC C)/AUC T)]
AUC C = Area under the curve for one component AUC T = the sum of the Area under the curve for all components.
56. A computer-implemented method for generating a data structure, tangibly embodied in a computer-readable medium, representing a quantitative value of a component of a polysaccharide, the method comprising an act of performing the calculation of claim 55.
57. The method of claim 50, wherein the component is signature component is one of the peaks corresponding to any one of .DELTA.UH NAC,6S GH NS,3S,6S, .DELTA.UH NS,6S GH NS,3S,6S ; .DELTA.UH NAC,6S GH NS,3S ; or .DELTA.UH NS,6S
GH NS,3S.
GH NS,3S.
58. Method of producing a composition of glycosaminoglycans comprising;
(A) performing a salt precipitation of a glycosaminoglycan-containing sample in a solvent to produce a first higher molecular weight fraction, and a second lower molecular weight fraction of isolated LMWH, and (B) processing the second fraction of isolated LMWH to produce a concentrated LMWH preparation.
(A) performing a salt precipitation of a glycosaminoglycan-containing sample in a solvent to produce a first higher molecular weight fraction, and a second lower molecular weight fraction of isolated LMWH, and (B) processing the second fraction of isolated LMWH to produce a concentrated LMWH preparation.
59. The method of claim 58, wherein the salt used in the precipitation step is a salt of divalent cations and weak anions.
60. The method of claim 58, wherein the salt is selected from elements from among the group comprising: barium calcium, magnesium, strontium, copper, silver, gold, nickel, cadmium, zinc, mercury, beryllium, palladium, platinum, iron, or tin.
61. The method of claim 59, wherein the salt of divalent cations and weak anions are acetates of cations of elements of the periodic table having divalent valence.
62. The method of claim 58, wherein the salt of the divalent cations and weak anions is selected from among the group comprising; barium acetate, calcium acetate, magnesium acetate, strontium acetate, copper acetate, nickel acetate, cadmium acetate, or calcium chloride.
63. The method of claim 58, wherein the salt of the divalent cations and weak anions is barium acetate.
64. The method of claim 58, wherein the salt of the divalent cations and weak anions is calcium acetate.
65. The method of claim 58, wherein the precipitation is performed at a temperature in a range of 0°C to 70°C.
66. The method of claim 58, wherein the precipitation is performed at a temperature of 4°C.
67. The method of claim 58, wherein the solvent is a polar solvent.
68. The method of claim 67 wherein the polar solvent is H2O, H2O mixed with ethanol, H2O mixed with acetone, or a combination of H2O, ethanol, and acetone.
69. The method of claim 67, wherein the polar solvent is a mixture of H2O, ethanol, and acetone.
70. The method of claim 58, wherein the processing of the second fraction to yield the concentrated LMWH preparation is an enzymatic digestion.
71. The method of claim 70, wherein the enzyme used for the enzymatic digestion is Heparinase III.
72. The method of claim 58 wherein the processing of the second fraction to yield the concentrated LMWH preparation is chemical degradation.
73. The method of claim 72 wherein the chemical degradation methods comprise: oxidative depolymerization with H2O2 or CU+ and H2O2; deaminative cleavage with isoamyl nitrite, or nitrous acid; .beta.-eliminative cleavage with benzyl ester of heparin by alkaline treatment or by heparinase.
74. The method of claim 58, wherein the glycosaminoglycan is selected from the group consisting of heparin, heparin analogs, LMWH, biotechnological heparin, chemically modified heparin, or synthetic heparin.
75. The method of claim 58, wherein the processing of the first fraction to yield the concentrated LMWH preparation is a purification step to produce a purified LMWH preparation.
76. The method of claim 75, further comprising formulating the purified LMWH preparation in a pharmaceutical carrier.
77. The method of claim 58, wherein the concentrated LMWH preparation is a LMWH preparation containing intact AT-binding domain.
78. The method of claim 58, further comprising the step of subjecting the second fraction to ion exchange chromatography prior to processing.
79. A composition comprising a LMWH preparation having an anti-Xa activity of at least 150 IU/mg.
80. The composition of claim 79, wherein the LMWH preparation has an anti-factor Xa:anti-factor IIa activity ratio of greater than 1.
81. The composition of claim 79, wherein the LMWH preparation has an anti-factor Xa:anti-factor IIa activity ratio of greater than 3.
82. The composition of claim 79, wherein the LMWH preparation has an anti-factor Xa:anti-factor IIa activity ratio of greater than 4.
83. The composition of claim 79, wherein the LMWH preparation has an anti-factor Xa:anti-factor IIa activity ratio of greater than 5.
84. The composition of claim 79, wherein the LMWH preparation is isolated.
85. The composition of claim 79, wherein the LMWH preparation is synthetic.
86. The composition of claim 79, wherein the LMWH preparation is formulated for subcutaneous delivery.
87. The composition of claim 79, wherein the LMWH preparation is formulated for intravenous delivery.
88. The composition of claim 79, wherein the LMWH preparation is formulated for aerosol delivery.
89. The composition of claim 79, wherein the LMWH preparation is formulated for oral delivery.
90. The composition of claim 79, wherein the LMWH preparation includes at least 3.5% .DELTA.UH NAC,6S GH NS,3S,6S, .DELTA.UH NS,6S GH NS,3S,6S;
.DELTA.UH NAC,6S GH NS,3S; or .DELTA.UH NS,6S GH NS,3S.
.DELTA.UH NAC,6S GH NS,3S; or .DELTA.UH NS,6S GH NS,3S.
91. The composition of claim 79, wherein the LMWH preparation includes at least 4.0% of one of the peaks corresponding to .DELTA.UH NAC,6S GH NS,3S,6S, .DELTA.UH NS,6S GH NS,3S,6S; .DELTA.UH NAC,6S GH NS,3S; or .DELTA.UH NS,6S GH
NS,3S.
NS,3S.
92. The composition of claim 79, wherein the LMWH preparation includes at least 5.0% of one of the peaks corresponding to .DELTA.UH NAC,6S GH NS,3S,6S, .DELTA.UH NS,6S GH NS,3S,6S; .DELTA.UN NAC,6S GH NS,3S; or .DELTA.UH NS,6S GH
NS,3S.
NS,3S.
93. A composition comprising a LMWH preparation having an anti-factor Xa:anti-factor IIa activity ratio of greater than 5.
94. A method for treating a subject having a condition, comprising;
(A) selecting a composition of LMWH having an identified level of AT-binding sequence, the level of AT-binding sequence selected depending on the condition to be treated in the subject, and (B) administering to a subject an effective amount of the composition of LMWH having an identified level of AT-binding sequence.
(A) selecting a composition of LMWH having an identified level of AT-binding sequence, the level of AT-binding sequence selected depending on the condition to be treated in the subject, and (B) administering to a subject an effective amount of the composition of LMWH having an identified level of AT-binding sequence.
95. The method of claim 94, wherein the subject has or is at risk of developing venous or arterial thromboembolic disease.
96. The method of claim 95, wherein the composition of LMWH is a LMWH
preparation including at least 3.5% of one of the peaks corresponding to .DELTA.UH NAC,6S GH NS,3S,6S, .DELTA.UN NS,6S GH NS,3S,6S; .DELTA.UH NAC,6S GH
NS,3S; or .DELTA.UH NS,6S GH NS,3S.
preparation including at least 3.5% of one of the peaks corresponding to .DELTA.UH NAC,6S GH NS,3S,6S, .DELTA.UN NS,6S GH NS,3S,6S; .DELTA.UH NAC,6S GH
NS,3S; or .DELTA.UH NS,6S GH NS,3S.
97. The method of claim 95, wherein the composition of LMWH is a LMWH
preparation including at least 4.0% of one of the peaks corresponding to .DELTA.UH NAC,6S GH NS,3S,6S, .DELTA.UH NS,6S GH NS,3S,6S; .DELTA.UH NAC,6S, GH NS,3S; or .DELTA.UH NS,6S GH NS,3S.
preparation including at least 4.0% of one of the peaks corresponding to .DELTA.UH NAC,6S GH NS,3S,6S, .DELTA.UH NS,6S GH NS,3S,6S; .DELTA.UH NAC,6S, GH NS,3S; or .DELTA.UH NS,6S GH NS,3S.
98. The method of claim 95, wherein the composition of LMWH is a LMWH
preparation including at least 5.0% of one of the peaks corresponding to .DELTA.UH NAC,6S GH NS,3S,6S, .DELTA.UH NS,6S GH NS,3S,6S; .DELTA.UH NAC,6S GH
NS,3S or .DELTA.UH NS,6S GH NS,3S.
preparation including at least 5.0% of one of the peaks corresponding to .DELTA.UH NAC,6S GH NS,3S,6S, .DELTA.UH NS,6S GH NS,3S,6S; .DELTA.UH NAC,6S GH
NS,3S or .DELTA.UH NS,6S GH NS,3S.
99. The method of claim 95, wherein the composition of LMWH is a LMWH
preparation having an anti-Xa activity of at least 150 IU/mg.
preparation having an anti-Xa activity of at least 150 IU/mg.
100. The method of claim 95, wherein the composition of LMWH is a LMWH
preparation having an anti-factor Xa:anti-factor IIa activity ratio of greater than 5.
preparation having an anti-factor Xa:anti-factor IIa activity ratio of greater than 5.
101. A composition comprising a LMWH preparation having at least 15%
disulfated disaccharides, less than 75% trisulfated disaccharides, 3-5%
monosulfated disaccharides, and at least 2% 4-7 tetrasaccharide.
disulfated disaccharides, less than 75% trisulfated disaccharides, 3-5%
monosulfated disaccharides, and at least 2% 4-7 tetrasaccharide.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23199400P | 2000-09-12 | 2000-09-12 | |
US60/231,994 | 2000-09-12 | ||
PCT/US2001/028457 WO2002023190A2 (en) | 2000-09-12 | 2001-09-12 | Methods and products related to low molecular weight heparin |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2422059A1 true CA2422059A1 (en) | 2002-03-21 |
CA2422059C CA2422059C (en) | 2012-05-15 |
Family
ID=22871450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2422059A Expired - Lifetime CA2422059C (en) | 2000-09-12 | 2001-09-12 | Methods and products related to low molecular weight heparin |
Country Status (12)
Country | Link |
---|---|
US (6) | US7083937B2 (en) |
EP (2) | EP1319183B1 (en) |
JP (2) | JP4911865B2 (en) |
AT (1) | ATE426805T1 (en) |
AU (1) | AU2001292618A1 (en) |
CA (1) | CA2422059C (en) |
CY (1) | CY1110323T1 (en) |
DE (1) | DE60138115D1 (en) |
DK (1) | DK1319183T3 (en) |
ES (2) | ES2324701T3 (en) |
PT (1) | PT1319183E (en) |
WO (1) | WO2002023190A2 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003527822A (en) | 1998-08-27 | 2003-09-24 | マサチューセッツ インスティテュート オブ テクノロジー | Rationally designed heparinases from heparinases I and II |
US7412332B1 (en) * | 1999-04-23 | 2008-08-12 | Massachusetts Institute Of Technology | Method for analyzing polysaccharides |
AU4351201A (en) * | 2000-03-08 | 2001-09-17 | Massachusetts Inst Technology | Heparinase iii and uses thereof |
PT1319183E (en) | 2000-09-12 | 2009-06-29 | Massachusetts Inst Technology | Methods and products related to low molecular weight heparin |
AU2440802A (en) | 2000-10-18 | 2002-04-29 | Massachusetts Inst Technology | Methods and products related to pulmonary delivery of polysaccharides |
WO2003033512A2 (en) * | 2001-10-16 | 2003-04-24 | Procognia, Ltd. | Method of preparing purified biologically active oligosaccharide libraries |
EP2284535A1 (en) | 2002-03-11 | 2011-02-16 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparins |
WO2003090696A2 (en) * | 2002-04-25 | 2003-11-06 | Momenta Pharmaceuticals, Inc. | Methods and products for mucosal delivery |
EP1575534B1 (en) * | 2002-05-03 | 2013-04-10 | Massachusetts Institute Of Technology | D4,5 glycuronidase and uses thereof |
WO2004055491A2 (en) | 2002-05-20 | 2004-07-01 | Massachusetts Institute Of Technology | Novel method for sequence determination using nmr |
EP1532241B1 (en) * | 2002-06-03 | 2010-09-15 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from chondroitinase b |
US20040171819A1 (en) | 2002-10-10 | 2004-09-02 | Aventis Pharma S.A. | Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
JP4606712B2 (en) * | 2003-01-08 | 2011-01-05 | マサチューセッツ インスティテュート オブ テクノロジー | 2-O sulfatase compositions and related methods |
DE10315581B4 (en) | 2003-04-05 | 2007-06-28 | Agilent Technologies, Inc. (n.d.Ges.d.Staates Delaware), Palo Alto | Method for quality determination of RNA samples |
CN102276732B (en) | 2003-11-28 | 2016-01-20 | 伊士曼化工公司 | Cellulose interpolymers and method for oxidation |
US7507570B2 (en) * | 2004-03-10 | 2009-03-24 | Massachusetts Institute Of Technology | Recombinant chondroitinase ABC I and uses thereof |
US20060057638A1 (en) * | 2004-04-15 | 2006-03-16 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
US20060127950A1 (en) * | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
TWI356036B (en) | 2004-06-09 | 2012-01-11 | Smithkline Beecham Corp | Apparatus and method for pharmaceutical production |
US20060002594A1 (en) * | 2004-06-09 | 2006-01-05 | Clarke Allan J | Method for producing a pharmaceutical product |
US8101244B2 (en) | 2004-06-09 | 2012-01-24 | Smithkline Beecham Corporation | Apparatus and method for producing or processing a product or sample |
EP1768687A2 (en) * | 2004-06-29 | 2007-04-04 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
WO2006083328A2 (en) * | 2004-09-15 | 2006-08-10 | Massachusetts Institute Of Technology | Biologically active surfaces and methods of their use |
DE102005038418A1 (en) * | 2005-08-12 | 2007-02-15 | Dade Behring Marburg Gmbh | Factor Xa-based heparin assay using a heparin-modifying component |
US7767420B2 (en) | 2005-11-03 | 2010-08-03 | Momenta Pharmaceuticals, Inc. | Heparan sulfate glycosaminoglycan lyase and uses thereof |
WO2007120478A2 (en) * | 2006-04-03 | 2007-10-25 | Massachusetts Institute Of Technology | Glycomic patterns for the detection of disease |
EP2019843A2 (en) | 2006-05-25 | 2009-02-04 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparin composition and uses thereof |
US8101733B1 (en) | 2006-06-27 | 2012-01-24 | Momenta Pharmaceuticals, Inc. | Methods of evaluating mixtures of polysaccharides |
CA2674493C (en) | 2007-01-05 | 2017-05-09 | Massachusetts Institute Of Technology | Compositions of and methods of using sulfatases from flavobacterium heparinum |
US7790466B1 (en) * | 2007-01-26 | 2010-09-07 | Momenta Pharmaceuticals, Inc. | Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping |
US7968082B1 (en) | 2007-01-26 | 2011-06-28 | Momenta Pharmaceuticals, Inc. | Evaluating mixtures of low molecular weight heparins by NMR |
US9139876B1 (en) | 2007-05-03 | 2015-09-22 | Momenta Pharmacueticals, Inc. | Method of analyzing a preparation of a low molecular weight heparin |
AU2010328726B2 (en) * | 2009-12-09 | 2017-01-19 | Agency For Science, Technology And Research | Glycosaminoglycan mixtures |
WO2011090948A1 (en) * | 2010-01-19 | 2011-07-28 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
JP5645493B2 (en) * | 2010-06-15 | 2014-12-24 | 川崎重工業株式会社 | Polysaccharide inspection apparatus and polysaccharide inspection method |
EP2598652A4 (en) | 2010-07-29 | 2014-04-30 | Shire Human Genetic Therapies | Assays for detection of glycosaminoglycans |
AU2015203727B2 (en) * | 2010-09-14 | 2016-05-26 | Fuso Pharmaceutical Industries, Ltd. | High Purity Heparin and Production Method Therefor |
KR102082276B1 (en) * | 2010-09-14 | 2020-02-27 | 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 | High purity heparin and production method therefor |
UA112070C2 (en) * | 2011-01-28 | 2016-07-25 | Хангжоу Джіуюан Джін Енджініерінг Ко., Лтд | METHOD OF CAPILLARY ELECTROPHORESIS FOR ANALYSIS OF Slim STRUCTURE OF Enoxaparin Sodium |
WO2012115952A1 (en) | 2011-02-21 | 2012-08-30 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
HUE036523T2 (en) * | 2011-12-19 | 2018-07-30 | Dilafor Ab | Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use |
WO2013095215A1 (en) * | 2011-12-19 | 2013-06-27 | Dilaforette Ab | Low anticoagulant heparins |
US20150017672A1 (en) * | 2012-02-01 | 2015-01-15 | Shire Human Genetic Therapies Inc. | Assays for detection of glycosaminoglycans |
ES2445494B1 (en) * | 2012-08-02 | 2015-03-06 | Rovi Lab Farmaceut Sa | Procedure for obtaining low and very low molecular weight heparins |
WO2022015794A1 (en) | 2020-07-14 | 2022-01-20 | Optimvia, Llc | Methods for synthesizing non-anticoagulant heparan sulfate |
CN114616340A (en) | 2019-07-09 | 2022-06-10 | 奥普蒂姆维亚有限公司 | Process for the synthesis of anticoagulant polysaccharides |
CN111019014A (en) * | 2019-11-22 | 2020-04-17 | 苏州二叶制药有限公司 | Preparation process of nadroparin calcium |
CN114264741B (en) * | 2021-12-15 | 2022-08-19 | 山东大学 | Method for identifying whether pig-derived heparin is doped with ruminant heparin |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1390633A (en) * | 1921-06-17 | 1921-09-13 | Edgar A Milhaupt | Bumper-bracket |
US4281108A (en) | 1980-01-28 | 1981-07-28 | Hepar Industries, Inc. | Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained |
US4341869A (en) | 1980-08-25 | 1982-07-27 | Massachusetts Institute Of Technology | Process for producing heparinase |
US4443545A (en) | 1980-08-25 | 1984-04-17 | Massachusetts Institute Of Technology | Process for producing heparinase |
US4373023A (en) | 1980-10-14 | 1983-02-08 | Massachusetts Institute Of Technology | Process for neutralizing heparin |
US4396762A (en) | 1981-08-24 | 1983-08-02 | Massachusetts Institute Of Technology | Heparinase derived anticoagulants |
US4551296A (en) | 1982-03-19 | 1985-11-05 | Allied Corporation | Producing high tenacity, high modulus crystalline article such as fiber or film |
FR2554348B1 (en) | 1983-11-04 | 1987-01-23 | Tissier Gerard | HEPARINIC COMPLEXES MARKED WITH SHORT LIFE RADIO ELEMENTS EMITTING NON-IONIZING RADIATIONS, PROCESS FOR OBTAINING THEM, INTERMEDIATE PRODUCTS AND APPLICATION OF SUCH COMPLEXES |
US4757056A (en) | 1984-03-05 | 1988-07-12 | Hepar Industries, Inc. | Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions |
US4679555A (en) | 1984-08-07 | 1987-07-14 | Key Pharmaceuticals, Inc. | Method and apparatus for intrapulmonary delivery of heparin |
US4847338A (en) * | 1985-03-28 | 1989-07-11 | University Of Iowa Research Foundation | Low molecular weight heparin fragments as inhibitors of complement activation |
FR2584728B1 (en) * | 1985-07-12 | 1987-11-20 | Choay Sa | PROCESS FOR THE SULFATION OF GLYCOSAMINOGLYCANS AND THEIR FRAGMENTS |
US5262403A (en) | 1986-03-10 | 1993-11-16 | Board Of Regents, The University Of Texas System | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II |
DK196986D0 (en) | 1986-04-30 | 1986-04-30 | Novo Industri As | PREPARATION OF POLYSACCHARIDES |
US5106734A (en) | 1986-04-30 | 1992-04-21 | Novo Nordisk A/S | Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin |
US4942156A (en) | 1986-08-20 | 1990-07-17 | Hepar Industries, Inc. | Low molecular weight heparin derivatives having improved anti-Xa specificity |
US4745105A (en) | 1986-08-20 | 1988-05-17 | Griffin Charles C | Low molecular weight heparin derivatives with improved permeability |
US4830013A (en) | 1987-01-30 | 1989-05-16 | Minnesota Mining And Manufacturing Co. | Intravascular blood parameter measurement system |
FR2614026B1 (en) | 1987-04-16 | 1992-04-17 | Sanofi Sa | LOW MOLECULAR WEIGHT HEPARINS WITH REGULAR STRUCTURE, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS |
SE8702254D0 (en) | 1987-05-29 | 1987-05-29 | Kabivitrum Ab | NOVEL HEPARIN DERIVATIVES |
US5217705A (en) | 1987-09-25 | 1993-06-08 | Neorx Corporation | Method of diagnosing blood clots using fibrin-binding proteins |
US5169772A (en) | 1988-06-06 | 1992-12-08 | Massachusetts Institute Of Technology | Large scale method for purification of high purity heparinase from flavobacterium heparinum |
IT1234508B (en) | 1988-06-10 | 1992-05-19 | Alfa Wassermann Spa | HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION |
US4981955A (en) * | 1988-06-28 | 1991-01-01 | Lopez Lorenzo L | Depolymerization method of heparin |
US5204323B1 (en) | 1988-10-06 | 1995-07-18 | Ciba Geigy Corp | Hirudin antidotal compositions and methods |
GB8826448D0 (en) | 1988-11-11 | 1988-12-14 | Thrombosis Res Inst | Improvements in/relating to organic compounds |
US5766573A (en) | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
IT1234826B (en) * | 1989-01-30 | 1992-05-29 | Alfa Wassermann Spa | HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION |
PT93847A (en) | 1989-04-24 | 1990-11-20 | Harvard College | PROCESS FOR THE PREPARATION OF OLIGOSACARIDES OF LOW MOLECULAR WEIGHT DERIVED FROM HEPARIN OR DESPOLYMENED HEPARAN SULFATE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
CA1340966C (en) | 1989-05-19 | 2000-04-18 | Thomas R. Covey | Method of protein analysis |
IT1237518B (en) | 1989-11-24 | 1993-06-08 | Renato Conti | SUPER-SULFATED HEPARINS |
GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
US5152784A (en) | 1989-12-14 | 1992-10-06 | Regents Of The University Of Minnesota | Prosthetic devices coated with a polypeptide with type IV collagen activity |
US5284558A (en) | 1990-07-27 | 1994-02-08 | University Of Iowa Research Foundation | Electrophoresis-based sequencing of oligosaccharides |
IT1245761B (en) | 1991-01-30 | 1994-10-14 | Alfa Wassermann Spa | PHARMACEUTICAL FORMULATIONS CONTAINING GLYCOSAMINOGLICANS ABSORBABLE ORALLY. |
JP3110064B2 (en) | 1991-03-06 | 2000-11-20 | 生化学工業株式会社 | Novel heparitinase, method for producing the same and bacteria producing the same |
US5262325A (en) | 1991-04-04 | 1993-11-16 | Ibex Technologies, Inc. | Method for the enzymatic neutralization of heparin |
JPH06507635A (en) | 1991-05-02 | 1994-09-01 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Compositions for the prevention and/or treatment of pathological processes |
WO1993005167A1 (en) | 1991-09-06 | 1993-03-18 | Children's Medical Center Corporation | Cell-type specific heparan sulfate proteoglycans and their uses |
US5714376A (en) | 1991-10-23 | 1998-02-03 | Massachusetts Institute Of Technology | Heparinase gene from flavobacterium heparinum |
AU3144993A (en) | 1991-11-21 | 1993-06-15 | Glyko, Inc. | Fluorophore-assisted therapeutic drug monitoring |
GB9202019D0 (en) | 1992-01-30 | 1992-03-18 | Imperial College | Methods and apparatus for assay of sulphated polysaccharides |
IT1254216B (en) | 1992-02-25 | 1995-09-14 | Opocrin Spa | POLYSACCHARIDIC DERIVATIVES OF HEPARIN, EPARAN SULPHATE, THEIR FRACTIONS AND FRAGMENTS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5453171A (en) | 1992-03-10 | 1995-09-26 | The Board Of Regents Of The University Of Michigan | Heparin-selective polymeric membrane electrode |
US5856928A (en) | 1992-03-13 | 1999-01-05 | Yan; Johnson F. | Gene and protein representation, characterization and interpretation process |
GB9206291D0 (en) | 1992-03-23 | 1992-05-06 | Cancer Res Campaign Tech | Oligosaccharides having growth factor binding affinity |
AU3938093A (en) | 1992-04-02 | 1993-11-08 | Baker Norton Pharmaceuticals, Inc. | Method and composition for treating antigen-induced and exercise-induced asthma |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5389539A (en) | 1992-11-30 | 1995-02-14 | Massachusetts Institute Of Technology | Purification of heparinase I, II, and III from Flavobacterium heparinum |
US5696100A (en) | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
GB9306255D0 (en) | 1993-03-25 | 1993-05-19 | Cancer Res Campaign Tech | Heparan sulphate oligosaccharides having hepatocyte growth factor binding affinity |
FR2704861B1 (en) | 1993-05-07 | 1995-07-28 | Sanofi Elf | Purified heparin fractions, process for obtaining them and pharmaceutical compositions containing them. |
US6770277B1 (en) * | 1993-06-23 | 2004-08-03 | Beckman Coulter, Inc. | Recombinant DNase B derived from streptococcus pyogenes |
EP0726773A1 (en) | 1993-11-17 | 1996-08-21 | Massachusetts Institute Of Technology | Method for inhibiting angiogenesis using heparinase |
US6013628A (en) | 1994-02-28 | 2000-01-11 | Regents Of The University Of Minnesota | Method for treating conditions of the eye using polypeptides |
US6376196B1 (en) * | 1996-05-10 | 2002-04-23 | The Regents Of The University Of California | Recombinant neospora antigens and their uses |
US5607859A (en) | 1994-03-28 | 1997-03-04 | Massachusetts Institute Of Technology | Methods and products for mass spectrometric molecular weight determination of polyionic analytes employing polyionic reagents |
US5753445A (en) | 1994-04-26 | 1998-05-19 | The Mount Sinai Medical Center Of The City University Of New York | Test for the detection of anti-heparin antibodies |
CA2189038A1 (en) | 1994-05-06 | 1995-11-09 | Kevin R. Holme | O-desulfated heparin derivatives, methods of making and uses thereof |
US5681733A (en) | 1994-06-10 | 1997-10-28 | Ibex Technologies | Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum |
US5619421A (en) | 1994-06-17 | 1997-04-08 | Massachusetts Institute Of Technology | Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure |
US5997863A (en) | 1994-07-08 | 1999-12-07 | Ibex Technologies R And D, Inc. | Attenuation of wound healing processes |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
FR2723847A1 (en) | 1994-08-29 | 1996-03-01 | Debiopharm Sa | HEPARIN - BASED ANTITHROMBOTIC AND NON - HEMORRHAGIC COMPOSITIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS. |
US5687090A (en) | 1994-09-01 | 1997-11-11 | Aspen Technology, Inc. | Polymer component characterization method and process simulation apparatus |
WO1996011671A1 (en) | 1994-10-12 | 1996-04-25 | Focal, Inc. | Targeted delivery via biodegradable polymers |
US5569366A (en) | 1995-01-27 | 1996-10-29 | Beckman Instruments, Inc. | Fluorescent labelled carbohydrates and their analysis |
US5618917A (en) | 1995-02-15 | 1997-04-08 | Arch Development Corporation | Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells |
US5763427A (en) | 1995-03-31 | 1998-06-09 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
JP3318578B2 (en) | 1995-05-26 | 2002-08-26 | サーモディックス,インコーポレイティド | Methods for promoting endothelialization and implantable products |
US5824299A (en) | 1995-06-22 | 1998-10-20 | President & Fellows Of Harvard College | Modulation of endothelial cell proliferation with IP-10 |
US5690910A (en) | 1995-08-18 | 1997-11-25 | Baker Norton Pharmaceuticals, Inc. | Method for treating asthma |
WO1997016556A1 (en) | 1995-10-30 | 1997-05-09 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from heparinase i |
US5752019A (en) | 1995-12-22 | 1998-05-12 | International Business Machines Corporation | System and method for confirmationally-flexible molecular identification |
GB9606188D0 (en) | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
ATE247948T1 (en) | 1996-04-29 | 2003-09-15 | Dura Pharma Inc | METHOD FOR INHALING DRY POWDER |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
AU3892297A (en) | 1996-07-26 | 1998-02-20 | Ikonos Corporation | Sensor for detecting heparin and other analytes |
JP2000516708A (en) * | 1996-08-08 | 2000-12-12 | ウィリアム・マーシュ・ライス・ユニバーシティ | Macroscopically operable nanoscale devices fabricated from nanotube assemblies |
US5759767A (en) | 1996-10-11 | 1998-06-02 | Joseph R. Lakowicz | Two-photon and multi-photon measurement of analytes in animal and human tissues and fluids |
EP0954282B1 (en) | 1997-01-16 | 2005-01-19 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5968822A (en) * | 1997-09-02 | 1999-10-19 | Pecker; Iris | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
US6190875B1 (en) * | 1997-09-02 | 2001-02-20 | Insight Strategy & Marketing Ltd. | Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
US6268146B1 (en) | 1998-03-13 | 2001-07-31 | Promega Corporation | Analytical methods and materials for nucleic acid detection |
JP2003527822A (en) | 1998-08-27 | 2003-09-24 | マサチューセッツ インスティテュート オブ テクノロジー | Rationally designed heparinases from heparinases I and II |
US7056504B1 (en) | 1998-08-27 | 2006-06-06 | Massachusetts Institute Of Technology | Rationally designed heparinases derived from heparinase I and II |
US6291439B1 (en) * | 1998-09-02 | 2001-09-18 | Biomarin Pharmaceuticals | Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin |
US6333051B1 (en) | 1998-09-03 | 2001-12-25 | Supratek Pharma, Inc. | Nanogel networks and biological agent compositions thereof |
US7412332B1 (en) | 1999-04-23 | 2008-08-12 | Massachusetts Institute Of Technology | Method for analyzing polysaccharides |
AU4351201A (en) | 2000-03-08 | 2001-09-17 | Massachusetts Inst Technology | Heparinase iii and uses thereof |
WO2001068815A1 (en) * | 2000-03-14 | 2001-09-20 | Es Cell International Pte Ltd | Embryonic stem cells and neural progenitor cells derived therefrom |
US6373194B1 (en) * | 2000-06-01 | 2002-04-16 | Raytheon Company | Optical magnetron for high efficiency production of optical radiation |
PT1319183E (en) * | 2000-09-12 | 2009-06-29 | Massachusetts Inst Technology | Methods and products related to low molecular weight heparin |
AU2440802A (en) | 2000-10-18 | 2002-04-29 | Massachusetts Inst Technology | Methods and products related to pulmonary delivery of polysaccharides |
US6777244B2 (en) * | 2000-12-06 | 2004-08-17 | Hrl Laboratories, Llc | Compact sensor using microcavity structures |
US20020071457A1 (en) * | 2000-12-08 | 2002-06-13 | Hogan Josh N. | Pulsed non-linear resonant cavity |
US20030008820A1 (en) | 2001-03-27 | 2003-01-09 | Massachusetts Institute Of Technology | Methods and products related to FGF dimerization |
US6788847B2 (en) * | 2001-04-05 | 2004-09-07 | Luxtera, Inc. | Photonic input/output port |
US7248297B2 (en) * | 2001-11-30 | 2007-07-24 | The Board Of Trustees Of The Leland Stanford Junior University | Integrated color pixel (ICP) |
US6828786B2 (en) * | 2002-01-18 | 2004-12-07 | California Institute Of Technology | Method and apparatus for nanomagnetic manipulation and sensing |
EP1575534B1 (en) | 2002-05-03 | 2013-04-10 | Massachusetts Institute Of Technology | D4,5 glycuronidase and uses thereof |
WO2004055491A2 (en) | 2002-05-20 | 2004-07-01 | Massachusetts Institute Of Technology | Novel method for sequence determination using nmr |
EP1532241B1 (en) | 2002-06-03 | 2010-09-15 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from chondroitinase b |
US6887773B2 (en) * | 2002-06-19 | 2005-05-03 | Luxtera, Inc. | Methods of incorporating germanium within CMOS process |
US8228959B2 (en) * | 2002-09-27 | 2012-07-24 | The Trustees Of Dartmouth College | Free electron laser, and associated components and methods |
US6922118B2 (en) * | 2002-11-01 | 2005-07-26 | Hrl Laboratories, Llc | Micro electrical mechanical system (MEMS) tuning using focused ion beams |
JP4606712B2 (en) | 2003-01-08 | 2011-01-05 | マサチューセッツ インスティテュート オブ テクノロジー | 2-O sulfatase compositions and related methods |
US7141800B2 (en) * | 2003-07-11 | 2006-11-28 | Charles E. Bryson, III | Non-dispersive charged particle energy analyzer |
US20050186679A1 (en) * | 2004-02-24 | 2005-08-25 | Christian Viskov | Method for determining specific groups constituting heparins or low molecular weight heparins |
US7851223B2 (en) | 2004-02-27 | 2010-12-14 | Roar Holding Llc | Method to detect emphysema |
US7507570B2 (en) | 2004-03-10 | 2009-03-24 | Massachusetts Institute Of Technology | Recombinant chondroitinase ABC I and uses thereof |
EP1582531A1 (en) * | 2004-03-24 | 2005-10-05 | Aventis Pharma S.A. | Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products |
US20060127950A1 (en) | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
WO2005110438A2 (en) | 2004-04-15 | 2005-11-24 | Massachusetts Institute Of Technology | Methods and products related to the intracellular delivery of polysaccharides |
US20060057638A1 (en) | 2004-04-15 | 2006-03-16 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
EP1768687A2 (en) | 2004-06-29 | 2007-04-04 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
US7586097B2 (en) * | 2006-01-05 | 2009-09-08 | Virgin Islands Microsystems, Inc. | Switching micro-resonant structures using at least one director |
WO2006083328A2 (en) | 2004-09-15 | 2006-08-10 | Massachusetts Institute Of Technology | Biologically active surfaces and methods of their use |
US20060187794A1 (en) * | 2004-10-14 | 2006-08-24 | Tim Harvey | Uses of wave guided miniature holographic system |
JP2008526258A (en) | 2005-01-12 | 2008-07-24 | マサチューセッツ・インスティテュート・オブ・テクノロジー | Methods and compositions relating to modulating the extracellular stem cell environment |
WO2006089206A2 (en) | 2005-02-16 | 2006-08-24 | Massachusetts Institute Of Technology | Methods to enhance carbon monoxide dehydrogenase activity and uses thereof |
WO2006105313A2 (en) | 2005-03-29 | 2006-10-05 | Massachusetts Institute Of Technology | Compositions of and methods of using oversulfated glycosaminoglycans |
WO2006105315A2 (en) | 2005-03-29 | 2006-10-05 | Massachusetts Institute Of Technology | Compositions and methods for regulating inflammatory responses |
US7619373B2 (en) * | 2006-01-05 | 2009-11-17 | Virgin Islands Microsystems, Inc. | Selectable frequency light emitter |
WO2007120478A2 (en) | 2006-04-03 | 2007-10-25 | Massachusetts Institute Of Technology | Glycomic patterns for the detection of disease |
CA2674493C (en) | 2007-01-05 | 2017-05-09 | Massachusetts Institute Of Technology | Compositions of and methods of using sulfatases from flavobacterium heparinum |
-
2001
- 2001-09-12 PT PT01972994T patent/PT1319183E/en unknown
- 2001-09-12 JP JP2002527786A patent/JP4911865B2/en not_active Expired - Fee Related
- 2001-09-12 CA CA2422059A patent/CA2422059C/en not_active Expired - Lifetime
- 2001-09-12 EP EP01972994A patent/EP1319183B1/en not_active Expired - Lifetime
- 2001-09-12 US US09/951,138 patent/US7083937B2/en not_active Expired - Lifetime
- 2001-09-12 DK DK01972994T patent/DK1319183T3/en active
- 2001-09-12 WO PCT/US2001/028457 patent/WO2002023190A2/en active Search and Examination
- 2001-09-12 DE DE60138115T patent/DE60138115D1/en not_active Expired - Lifetime
- 2001-09-12 ES ES01972994T patent/ES2324701T3/en not_active Expired - Lifetime
- 2001-09-12 AU AU2001292618A patent/AU2001292618A1/en not_active Abandoned
- 2001-09-12 AT AT01972994T patent/ATE426805T1/en active
- 2001-09-12 ES ES08172045.0T patent/ES2640975T3/en not_active Expired - Lifetime
- 2001-09-12 EP EP08172045.0A patent/EP2085780B1/en not_active Expired - Lifetime
-
2005
- 2005-07-15 US US11/183,323 patent/US7399604B2/en not_active Expired - Lifetime
-
2006
- 2006-09-08 US US11/518,534 patent/US7687479B2/en not_active Expired - Fee Related
- 2006-11-30 US US11/606,623 patent/US7585642B2/en not_active Expired - Fee Related
-
2009
- 2009-06-02 CY CY20091100585T patent/CY1110323T1/en unknown
- 2009-07-27 US US12/509,774 patent/US8173384B2/en not_active Expired - Lifetime
-
2011
- 2011-04-26 JP JP2011098811A patent/JP5186019B2/en not_active Expired - Fee Related
-
2012
- 2012-05-07 US US13/465,639 patent/US8512969B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2085780A3 (en) | 2011-08-17 |
CA2422059C (en) | 2012-05-15 |
EP2085780A2 (en) | 2009-08-05 |
EP2085780B1 (en) | 2017-06-21 |
WO2002023190A8 (en) | 2011-10-27 |
ES2324701T3 (en) | 2009-08-13 |
JP5186019B2 (en) | 2013-04-17 |
WO2002023190A3 (en) | 2003-03-13 |
US7687479B2 (en) | 2010-03-30 |
US8173384B2 (en) | 2012-05-08 |
US20130017565A1 (en) | 2013-01-17 |
DE60138115D1 (en) | 2009-05-07 |
JP2011169913A (en) | 2011-09-01 |
US7083937B2 (en) | 2006-08-01 |
ES2640975T3 (en) | 2017-11-07 |
US7399604B2 (en) | 2008-07-15 |
PT1319183E (en) | 2009-06-29 |
US20100062468A1 (en) | 2010-03-11 |
EP1319183B1 (en) | 2009-03-25 |
US20020169143A1 (en) | 2002-11-14 |
DK1319183T3 (en) | 2009-05-18 |
US20060024664A1 (en) | 2006-02-02 |
US20070161073A1 (en) | 2007-07-12 |
JP4911865B2 (en) | 2012-04-04 |
AU2001292618A1 (en) | 2002-03-26 |
EP1319183A2 (en) | 2003-06-18 |
US20070065921A1 (en) | 2007-03-22 |
US8512969B2 (en) | 2013-08-20 |
WO2002023190A2 (en) | 2002-03-21 |
ATE426805T1 (en) | 2009-04-15 |
US7585642B2 (en) | 2009-09-08 |
JP2004509339A (en) | 2004-03-25 |
CY1110323T1 (en) | 2014-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2422059A1 (en) | Methods and products related to low molecular weight heparin | |
JP2004509339A5 (en) | ||
Rosenberg et al. | Correlation between structure and function of heparin | |
Shively et al. | Stoichiometry of the nitrous acid deaminative cleavage of model amino sugar glycosides and glycosaminoglycuronans | |
Loganathan et al. | Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources | |
Linhardt et al. | Examination of the substrate specificity of heparin and heparan sulfate lyases | |
Zhang et al. | Structural characterization of heparins from different commercial sources | |
Nielsen et al. | Determination of urinary oligosaccharides by high-performance liquid chromatography/electrospray ionization–tandem mass spectrometry: application to Hunter syndrome | |
CA2478700A1 (en) | Analysis of sulfated polysaccharides | |
EP2526122B1 (en) | Evaluating heparin preparations | |
AU2005224415B2 (en) | Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same | |
Linhardt et al. | Search for the heparin antithrombin III-binding site precursor. | |
CA2558559A1 (en) | Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products | |
AU2003233255B2 (en) | Oligosaccharide biomarkers for mucopolysaccharidoses and other related disorders | |
Wang et al. | Liquid chromatography–diode array detection–mass spectrometry for compositional analysis of low molecular weight heparins | |
EP2667186B1 (en) | Fine structure determination method of enoxaparin sodium based on capillary electrophoresis | |
EP1752772A1 (en) | Assay for determination of heparin based on factor Xa using a heparin-modifying component | |
EP2642288A1 (en) | Profiling oligosaccharides associated with biological activities of heparin or heparin derivatives | |
Kailemia et al. | Differentiating chondroitin sulfate glycosaminoglycans using collision-induced dissociation; uronic acid cross-ring diagnostic fragments in a single stage of tandem mass spectrometry | |
Chen et al. | Analysis of heparinase derived LMWH products using a MHC 2D LC system linked to Q-TOF MS | |
Zhu et al. | Heparin contamination and issues related to raw materials and controls | |
Yan et al. | Characterization of degradation products of carrageenan by LC-QTOF/MS with a hypothetical database | |
Yi et al. | Qualitative and quantitative analysis of 2, 5-anhydro-d-mannitol in low molecular weight heparins with high performance anion exchange chromatography hyphenated quadrupole time of flight mass spectrometry | |
Kailemia et al. | Differentiating chondroitin sulfate glycosaminoglycans using CID; uronic acid cross-ring diagnostic fragments in a single stage of MS/MS | |
Rudd et al. | New Methods for the Analysis of Heterogeneous Polysaccharides–Lessons Learned from the Heparin Crisis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20210913 |